https://www.nasdaq.com/press-release/abcellera-announces-changes-to-its-board-of-directors-2021-12-07
https://www.nasdaq.com/press-release/abcellera-discovered-bamlanivimab-together-with-etesevimab-authorized-as-the-first
https://www.nasdaq.com/press-release/abcellera-announces-the-appointment-of-neil-aubuchon-as-chief-commercial-officer-2021
https://www.nasdaq.com/press-release/abcellera-reports-q3-2021-business-results-2021-11-09
https://www.nasdaq.com/press-release/abcellera-announces-virtual-presentations-at-investor-conferences-in-november-2021-11
https://www.nasdaq.com/press-release/lilly-to-supply-614000-additional-doses-of-abcellera-discovered-bamlanivimab-together
https://www.nasdaq.com/press-release/abcellera-to-report-third-quarter-2021-financial-results-on-november-9-2021-2021-10
https://www.nasdaq.com/press-release/abcellera-and-everest-medicines-announce-multi-target-collaboration-to-advance-new
https://www.nasdaq.com/press-release/abcellera-and-everest-medicines-announce-multi-target-collaboration-to-advance-new-0
https://www.nasdaq.com/press-release/lilly-to-supply-the-eu-and-eea-with-up-to-220000-doses-of-abcellera-discovered
https://www.nasdaq.com/press-release/emergency-use-authorization-of-abcellera-discovered-bamlanivimab-administered-with
https://www.nasdaq.com/press-release/abcellera-announces-collaboration-with-moderna-to-discover-therapeutic-antibodies-for
https://www.nasdaq.com/press-release/abcellera-acquires-tetragenetics-enhancing-capabilities-to-generate-antibodies
https://www.nasdaq.com/press-release/abcellera-to-present-virtually-at-the-bofa-securities-tech-solutions-for-drug
https://www.nasdaq.com/press-release/abcellera-reports-q2-2021-business-results-2021-08-12
https://www.nasdaq.com/press-release/eqrx-and-abcellera-announce-collaboration-to-accelerate-the-advancement-of-new
https://www.nasdaq.com/press-release/tachyon-and-abcellera-collaborate-to-develop-novel-antibody-therapeutic-targeting-tgf
https://www.nasdaq.com/press-release/abcellera-to-report-second-quarter-2021-financial-results-on-august-12-2021-2021-07
https://www.nasdaq.com/press-release/abcellera-appoints-neil-berkley-as-chief-business-officer-2021-07-13
https://www.nasdaq.com/press-release/abcellera-continues-expansion-and-strengthens-future-pandemic-preparedness-with-first
https://www.nasdaq.com/press-release/abcellera-announces-secondary-private-sale-of-11.9-million-common-shares-2021-06-10
https://www.nasdaq.com/press-release/correcting-and-replacing-abcellera-reports-q1-2021-business-results-2021-05-14
https://www.nasdaq.com/press-release/abcellera-to-present-virtually-at-berenberg-conference-on-may-18-2021-2021-05-13
https://www.nasdaq.com/press-release/abcellera-partners-with-angios-to-develop-therapeutics-to-combat-blindness-caused-by
https://www.nasdaq.com/press-release/new-abcellera-discovered-antibody-that-neutralizes-viral-variants-of-covid-19-ly
https://www.nasdaq.com/press-release/abcellera-breaks-ground-on-global-headquarters-in-vancouver-and-expects-to-hire
https://www.nasdaq.com/press-release/abcellera-to-report-first-quarter-2021-financial-results-on-may-13-2021-2021-04-21
https://www.nasdaq.com/press-release/abcellera-and-empirico-announce-strategic-multi-target-antibody-discovery
https://www.nasdaq.com/press-release/abcellera-to-present-virtually-at-upcoming-investor-conferences-2021-04-12
https://www.nasdaq.com/press-release/published-peer-reviewed-data-demonstrate-bamlanivimabs-high-potency-against-sars-cov
https://www.nasdaq.com/press-release/abcellera-and-gilead-sciences-announce-new-multi-year-multi-target-antibody-discovery
https://www.nasdaq.com/press-release/abcellera-reports-full-year-2020-business-results-2021-03-29
https://www.nasdaq.com/press-release/abcellera-discovered-bamlanivimab-together-with-etesevimab-reduced-hospitalizations
https://www.nasdaq.com/press-release/ema-advises-use-of-abcellera-discovered-bamlanivimab-alone-or-together-with
https://www.nasdaq.com/press-release/abcellera-to-present-at-the-svb-leerink-global-healthcare-conference-2021-02-17
https://www.nasdaq.com/press-release/abcellera-appoints-ester-falconer-ph.d.-as-chief-technology-officer-2021-02-11
https://www.nasdaq.com/press-release/abcellera-discovered-antibody-bamlanivimab-administered-with-etesevimab-receives-fda
https://www.nasdaq.com/press-release/abcellera-announces-date-of-fourth-quarter-2020-financial-results-conference-call
https://www.nasdaq.com/press-release/abcellera-discovered-antibody-bamlanivimab-to-be-developed-with-vir-7831-for-the
https://www.nasdaq.com/press-release/abcellera-discovered-antibody-bamlanivimab-administered-with-etesevimab-reduced-risk
https://www.nasdaq.com/press-release/abcellera-discovered-antibody-prevented-covid-19-in-nursing-homes-and-reduced-risks
https://www.nasdaq.com/press-release/abcellera-granted-u.s.-patent-covering-its-trianni-mouser-technology-2021-01-19
https://www.nasdaq.com/press-release/abcellera-discovered-neutralizing-antibody-for-covid-19-enters-new-pragmatic-study-in
https://www.nasdaq.com/press-release/abcellera-announces-closing-of-initial-public-offering-and-exercise-in-full-of-the
